1075-00-9

Basic information

• Product Name: 8-Fluoroisoquinoline
• Synonyms: 8-Fluoroisoquinoline;8-Fluoro-2-azanaphthalene
• CAS NO: 1075-00-9
• Molecular Formula: C₉H₆FN
• Molecular Weight: 147.15
• Product Categories: blocks;FluoroCompounds;Quinolines;Heterocyclic Series
• Mol File: 1075-00-9.mol

Chemical Properties

• Boiling Point: 255.3°Cat760mmHg
• Flash Point: 108.2°C
• Appearance: /
• Density: 1.216g/cm³
• Vapor Pressure: 0.0264mmHg at 25°C
• Refractive Index: 1.614
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.82±0.23(Predicted)
• CAS DataBase Reference: 8-Fluoroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Fluoroisoquinoline(1075-00-9)
• EPA Substance Registry System: 8-Fluoroisoquinoline(1075-00-9)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 1075-00-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
8-Fluoroisoquinoline is utilized as a key intermediate in the synthesis of various pharmaceuticals, including antitumor and antiviral agents. Its unique structure and properties make it a valuable component in the development of new drugs with potential therapeutic applications.
Used in the Creation of Functional Materials:
Beyond its pharmaceutical applications, 8-Fluoroisoquinoline is also employed in the design and synthesis of functional materials. Its chemical properties and structural features contribute to the development of materials with specific characteristics, such as improved stability, reactivity, or selectivity, depending on the intended application.
The exact properties of 8-Fluoroisoquinoline, such as its melting point, boiling point, or solubility, can vary depending on the presence of additional functional groups attached to its core structure. This variability allows for the fine-tuning of its properties to suit specific applications in various industries.

InChI:InChI=1/C9H6FN/c10-9-3-1-2-7-4-5-11-6-8(7)9/h1-6H

Upstream product

• 446-52-6 2-Fluorobenzaldehyde 
• 1404367-16-3 N-(2,2-dimethoxyethyl)-N-(2-fluorobenzyl)-4-methylbenzenesulfonamide 
• 1178920-49-4 N-(2-fluorobenzyl)-2,2-dimethoxyethanamine 
• 608515-45-3 2-fluoro-6-(2-(trimethylsilyl)ethynyl)benzaldehyde 
• 444898-80-0 (2-fluorobenzylidene)(2,2-dimethoxyethyl)amine 

Downstream Products

• 1159997-87-1 2-benzyl-8-fluoroisoquinolinium bromide 
• 1404367-17-4 4-bromo-8-fluoroisoquinoline 
• 123594-01-4 8-fluoro-1,2,3,4-tetrahydroisoquinoline 
• 1159997-88-2 2-benzyl-8-fluoro-1-(4-(trifluoromethyl)phenyl)-1,2-dihydroisoquinoline 
• 444898-84-4 8-fluoro-2H-isoquinolin-1-one 

Relevant articles and documents

SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME

The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient.

SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF

Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS

Tetrahydroisoquinoline compounds of formula (I), and compositions containing them, for the treatment of acute, inflammatory and neurophatic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neurophatic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintened pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Synthesis of novel substituted isoquinolones

A series of novel substituted isoquinolones have been synthesised. This has been achieved by two routes, either Curtius rearrangment of cinnamic acids or via an isoquinoline N-oxide.